Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
TP53 and leukemia are reported together in 10 articles.
Gene
TP53
- HGNC
- HGNC:11998
219articles
219mentions
7variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 43colorectal cancer 32leukemia 10hepatocellular carcinoma 9ovarian cancer 6thyroid cancer 5lung cancer 4obesity 4
Reported variants (articles · ClinVar status)
Phenotype
Leukemia
652articles
652mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
10 records shown · first 60Biomarkers and advances in AML-MRC: from bench to bedside.
PMID 41711916 | PMCID PMC12920406 | DOI 10.1007/s00277-026-06805-8 · Annals of hematology · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) represents a high-risk subtype of AML, characterized by poor prognosis and limited therapeutic options.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | RUNX1 | “This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Additionally, we discuss emerging therapies, including CPX-351, hypomethylating agents (HMAs), targeted inhibitors (e.g., FLT3 and IDH1/2 inhibitors), and immunotherapies, while addressing the challenges of treatment resistance and relapse.” | 0.98 | hgnc_dict_v1 |
HTLV-1-Driven Clonal Evolution and Immune Escape in Adult T-Cell Leukaemia: From Viral Persistence to Therapeutic Failure.
PMID 42066066 | DOI 10.1002/rmv.70162 · Reviews in medical virology · 2026 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “Despite the use of antiviral therapies and targeted monoclonal antibodies, therapeutic failure is common due to genomic instability-specifically TP53 mutations compromising Zidovudine/Interferon efficacy and CCR4 antigenic variations leading to mogamulizumab resistance.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “HTLV-1-Driven Clonal Evolution and Immune Escape in Adult T-Cell Leukaemia: From Viral Persistence to Therapeutic Failure.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | CCR4 | “Despite the use of antiviral therapies and targeted monoclonal antibodies, therapeutic failure is common due to genomic instability-specifically TP53 mutations compromising Zidovudine/Interferon efficacy and CCR4 antigenic variations leading to mogamulizumab resistance.” | 0.98 | hgnc_dict_v1 |
| phenotype | lymphoma | “Adult T-cell leukaemia/lymphoma (ATL) is an aggressive CD4 +T-cell malignancy caused by the human T-cell leukaemia virus type 1 (HTLV-1).” | 0.98 | phenotype_alias_lexicon_v2 |
Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes.
PMID 41175395 | DOI 10.1080/14737140.2025.2582649 · Expert review of anticancer therapy · 2026 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “TP53 aberrations were found in 9.0% of CLL-treated and 9.8% of TN cohorts.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes.” | 0.93 | phenotype_alias_lexicon_v2 |
Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing.
PMID 41355924 | PMCID PMC12678951 | DOI 10.5306/wjco.v16.i11.111983 · World journal of clinical oncology · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “ML identified three BC-CML clusters: (1) Cluster 1 [breast cancer susceptibility gene 2 (BRCA2), TP53]; (2) Cluster 2 [isocitrate dehydrogenase (IDH) 1/2, ten-eleven translocation 2]; and (3) Cluster 3 [Janus kinase (JAK) 2, colony-stimulating factor 3 receptor], with distinct COSMIC signatures.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “BACKGROUND: Although chronic-phase chronic myeloid leukemia (CP-CML) is treatable and nearly curable in about 50% of patients, accelerated-phase chronic myeloid leukemia (AP-CML) shows concerning drug resistance, while blast crisis chronic myeloid leukemia (BC-CML) is highly lethal.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA2 | “ML identified three BC-CML clusters: (1) Cluster 1 [breast cancer susceptibility gene 2 (BRCA2), TP53]; (2) Cluster 2 [isocitrate dehydrogenase (IDH) 1/2, ten-eleven translocation 2]; and (3) Cluster 3 [Janus kinase (JAK) 2, colony-stimulating factor 3 receptor], with distinct COSMIC signatures.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “ML identified three BC-CML clusters: (1) Cluster 1 [breast cancer susceptibility gene 2 (BRCA2), TP53]; (2) Cluster 2 [isocitrate dehydrogenase (IDH) 1/2, ten-eleven translocation 2]; and (3) Cluster 3 [Janus kinase (JAK) 2, colony-stimulating factor 3 receptor], with distinct COSMIC signatures.” | 0.98 | phenotype_alias_lexicon_v2 |
TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies.
PMID 40909943 | PMCID PMC12405186 | DOI 10.3389/fonc.2025.1655486 · Frontiers in oncology · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “TP53 mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | MDM2 | “However, novel therapeutic approaches provide promising avenues, including MDM2 inhibitors, p53-reactivating agents, pathway-targeted inhibitors (Hedgehog, Wnt, NF-κB), immune modulation (checkpoint inhibitors, CAR-T therapy), metabolic interventions (fatty acid metabolism, glycolysis), and gene-editing technologies (CRISPR/Cas9, base editing).” | 0.98 | hgnc_dict_v1 |
Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies.
PMID 38204493 | PMCID PMC10777859 | DOI 10.2147/IJGM.S437327 · International journal of general medicine · 2024 · 13 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “PURPOSE: Genetic mutations are major factors in the diagnosis and prognosis of leukemia, and it is difficult to assess these variants using single-gene analysis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CALR | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
| gene | IDH1 | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
Li-Fraumeni Syndrome with Unusual Synchronous Malignancies: A Case Report.
PMID 38188481 | PMCID PMC10769503 | DOI 10.1159/000535099 · Case reports in oncology · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “INTRODUCTION: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the TP53 tumor suppressor gene.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “CASE PRESENTATION: We are presenting a 48-year-old male with a diagnosis of LFS that was confirmed by a genetic test triggered by the patient's son's diagnosis of LFS and leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | gastric cancer | “CONCLUSION: Gastric cancer and neuroendocrine tumors are not usually associated with LFS.” | 0.98 | phenotype_alias_lexicon_v2 |
TP53 Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia.
PMID 35328276 | PMCID PMC8946951 | DOI 10.3390/diagnostics12030724 · Diagnostics (Basel, Switzerland) · 2022 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “TP53 Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Most of the 6 patients with TP53 deletion had acute lymphoblastic leukemia (ALL), and majority of them were child.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia, Jeddah | “TP53 Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia. Nevertheless, the prevalence and prognostic role of TP53 mutations in hematological malignancy in Saudi patients are not well reported. We, therefore, aim to assess the frequency of TP53 mutations in hematological malignancies in Saudi Arabia. Most of the 6 patients with TP53 deletion had acute lymphoblastic leukemia (ALL), and majority of them were child.” | 0.95 | saudi_context_rules_v1 |
| variant | p.H175R | “G9963A, p.H175R).” | 0.95 | hgvs_regex_v1 |
Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia.
PMID 32359129 | DOI 10.1002/pbc.28340 · Pediatric blood & cancer · 2020 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “Three patients with B-ALL had heterozygous pathogenic mutations in TP53, BRCA1, and BRCA2; one patient with B-ALL had homozygous pathogenic mutation in PMS2; and one patient with T-ALL had LP homozygous mutation in AK2 that was associated with reticular dysgenesis.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “Three patients with B-ALL had heterozygous pathogenic mutations in TP53, BRCA1, and BRCA2; one patient with B-ALL had homozygous pathogenic mutation in PMS2; and one patient with T-ALL had LP homozygous mutation in AK2 that was associated with reticular dysgenesis.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA2 | “Three patients with B-ALL had heterozygous pathogenic mutations in TP53, BRCA1, and BRCA2; one patient with B-ALL had homozygous pathogenic mutation in PMS2; and one patient with T-ALL had LP homozygous mutation in AK2 that was associated with reticular dysgenesis.” | 0.98 | hgnc_dict_v1 |
Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients.
PMID 24961464 | DOI 10.1007/s12032-014-0038-0 · Medical oncology (Northwood, London, England) · 2014 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “Therefore, have investigated whether or not the expression levels, of selected genes [tumor necrosis factor-α (TNFα), interleukin 6 (IL-6), adiponectin, leptin, C-reactive protein (CRP), parathyroid hormone (PTH), tumor protein 53 (TP53) and erythroblastic leukemia viral oncogene 2 (ErbB2)] were altered in blood samples of lean, overweight/obese and breast cancer subjects.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Therefore, have investigated whether or not the expression levels, of selected genes [tumor necrosis factor-α (TNFα), interleukin 6 (IL-6), adiponectin, leptin, C-reactive protein (CRP), parathyroid hormone (PTH), tumor protein 53 (TP53) and erythroblastic leukemia viral oncogene 2 (ErbB2)] were altered in blood samples of lean, overweight/obese and breast cancer subjects.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TNF | “Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients.” | 0.98 | hgnc_dict_v1 |
| gene | CRP | “Therefore, have investigated whether or not the expression levels, of selected genes [tumor necrosis factor-α (TNFα), interleukin 6 (IL-6), adiponectin, leptin, C-reactive protein (CRP), parathyroid hormone (PTH), tumor protein 53 (TP53) and erythroblastic leukemia viral oncogene 2 (ErbB2)] were altered in blood samples of lean, overweight/obese and breast cancer subjects.” | 0.98 | hgnc_dict_v1 |